Immunogenicity of trivalent influenza vaccines in patients with chronic kidney disease undergoing hemodialysis: MF59-adjuvanted versus non-adjuvanted vaccines

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Backgrounds: Patients with chronic kidney disease (CKD) are at an increased risk of morbidity and mortality from influenza. However, the immunogenicity of influenza vaccine is known to be attenuated in these patients. In this study, the immunogenicity of MF59-adjuvanted and non-adjuvanted trivalent influenza vaccines was compared in CKD patients undergoing hemodialysis (HD). Methods: During 2013–2014, 179 CKD patients undergoing HD participated in the study. The patients were randomized into either MF59-adjuvanted vaccine group or non-adjuvanted vaccine group and were immunized with the respective vaccine. Sera were collected prior to vaccination and at 1 month (88 patients in MF59-adjuvanted vaccine group and 86 patients in non-adjuvanted vaccine group) and 6 months post vaccination. Levels of hemagglutination inhibition antibodies were measured. Results: The seroconversion rate of all 3 vaccine strains at 1 month post-vaccination was significantly higher in the MF59-adjuvanted group than in the non-adjuvanted group (47.7% vs. 17.4%, A/H1N1; 42.0% vs. 16.3%, A/H3N2; 31.8% vs. 7.0%, B, P < 0.01). One month post-vaccination, the fold increase in geometric mean titer from pre-vaccination for A/H1N1, A/H3N2 and B viruses was significantly greater in the MF59-adjuvanted group than in the non-adjuvanted group. In elderly patients (≥65 years), the seroconversion rate at 1 month post-vaccination against influenza B strain was higher in the MF59-adjuvanted group than in the non-adjuvanted group (33.3% vs. 7.1%, P = 0.03). Conclusion: The MF59-adjuvanted influenza vaccine showed better immunogenicity than the non-adjuvanted influenza vaccine in CKD patients undergoing HD.

Original languageEnglish
Pages (from-to)2902-2908
Number of pages7
JournalHuman Vaccines and Immunotherapeutics
Volume12
Issue number11
DOIs
Publication statusPublished - 2016 Nov 1

Fingerprint

Influenza Vaccines
Chronic Renal Insufficiency
Renal Dialysis
Vaccines
Vaccination
Human Influenza
H3N2 Subtype Influenza A Virus
Cercopithecine Herpesvirus 1
MF59 oil emulsion
Hemagglutination
Morbidity
Mortality
Antibodies

Keywords

  • influenza vaccines
  • MF59 oil emulsion
  • renal dialysis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology

Cite this

@article{ed648149020844f8824c2c7b5c252cb7,
title = "Immunogenicity of trivalent influenza vaccines in patients with chronic kidney disease undergoing hemodialysis: MF59-adjuvanted versus non-adjuvanted vaccines",
abstract = "Backgrounds: Patients with chronic kidney disease (CKD) are at an increased risk of morbidity and mortality from influenza. However, the immunogenicity of influenza vaccine is known to be attenuated in these patients. In this study, the immunogenicity of MF59-adjuvanted and non-adjuvanted trivalent influenza vaccines was compared in CKD patients undergoing hemodialysis (HD). Methods: During 2013–2014, 179 CKD patients undergoing HD participated in the study. The patients were randomized into either MF59-adjuvanted vaccine group or non-adjuvanted vaccine group and were immunized with the respective vaccine. Sera were collected prior to vaccination and at 1 month (88 patients in MF59-adjuvanted vaccine group and 86 patients in non-adjuvanted vaccine group) and 6 months post vaccination. Levels of hemagglutination inhibition antibodies were measured. Results: The seroconversion rate of all 3 vaccine strains at 1 month post-vaccination was significantly higher in the MF59-adjuvanted group than in the non-adjuvanted group (47.7{\%} vs. 17.4{\%}, A/H1N1; 42.0{\%} vs. 16.3{\%}, A/H3N2; 31.8{\%} vs. 7.0{\%}, B, P < 0.01). One month post-vaccination, the fold increase in geometric mean titer from pre-vaccination for A/H1N1, A/H3N2 and B viruses was significantly greater in the MF59-adjuvanted group than in the non-adjuvanted group. In elderly patients (≥65 years), the seroconversion rate at 1 month post-vaccination against influenza B strain was higher in the MF59-adjuvanted group than in the non-adjuvanted group (33.3{\%} vs. 7.1{\%}, P = 0.03). Conclusion: The MF59-adjuvanted influenza vaccine showed better immunogenicity than the non-adjuvanted influenza vaccine in CKD patients undergoing HD.",
keywords = "influenza vaccines, MF59 oil emulsion, renal dialysis",
author = "Noh, {Ji Yun} and Joon-Young Song and Wonseok Choi and Jacob Lee and Seo, {Yu Bin} and Young-Joo Kwon and Ko, {Gang Jee} and Dae-Ryong Cha and Kang, {Young Sun} and Lee, {Young Ki} and Hee-Jin Cheong and Kim, {Woo Joo}",
year = "2016",
month = "11",
day = "1",
doi = "10.1080/21645515.2016.1191717",
language = "English",
volume = "12",
pages = "2902--2908",
journal = "Human Vaccines and Immunotherapeutics",
issn = "2164-5515",
publisher = "Landes Bioscience",
number = "11",

}

TY - JOUR

T1 - Immunogenicity of trivalent influenza vaccines in patients with chronic kidney disease undergoing hemodialysis

T2 - MF59-adjuvanted versus non-adjuvanted vaccines

AU - Noh, Ji Yun

AU - Song, Joon-Young

AU - Choi, Wonseok

AU - Lee, Jacob

AU - Seo, Yu Bin

AU - Kwon, Young-Joo

AU - Ko, Gang Jee

AU - Cha, Dae-Ryong

AU - Kang, Young Sun

AU - Lee, Young Ki

AU - Cheong, Hee-Jin

AU - Kim, Woo Joo

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Backgrounds: Patients with chronic kidney disease (CKD) are at an increased risk of morbidity and mortality from influenza. However, the immunogenicity of influenza vaccine is known to be attenuated in these patients. In this study, the immunogenicity of MF59-adjuvanted and non-adjuvanted trivalent influenza vaccines was compared in CKD patients undergoing hemodialysis (HD). Methods: During 2013–2014, 179 CKD patients undergoing HD participated in the study. The patients were randomized into either MF59-adjuvanted vaccine group or non-adjuvanted vaccine group and were immunized with the respective vaccine. Sera were collected prior to vaccination and at 1 month (88 patients in MF59-adjuvanted vaccine group and 86 patients in non-adjuvanted vaccine group) and 6 months post vaccination. Levels of hemagglutination inhibition antibodies were measured. Results: The seroconversion rate of all 3 vaccine strains at 1 month post-vaccination was significantly higher in the MF59-adjuvanted group than in the non-adjuvanted group (47.7% vs. 17.4%, A/H1N1; 42.0% vs. 16.3%, A/H3N2; 31.8% vs. 7.0%, B, P < 0.01). One month post-vaccination, the fold increase in geometric mean titer from pre-vaccination for A/H1N1, A/H3N2 and B viruses was significantly greater in the MF59-adjuvanted group than in the non-adjuvanted group. In elderly patients (≥65 years), the seroconversion rate at 1 month post-vaccination against influenza B strain was higher in the MF59-adjuvanted group than in the non-adjuvanted group (33.3% vs. 7.1%, P = 0.03). Conclusion: The MF59-adjuvanted influenza vaccine showed better immunogenicity than the non-adjuvanted influenza vaccine in CKD patients undergoing HD.

AB - Backgrounds: Patients with chronic kidney disease (CKD) are at an increased risk of morbidity and mortality from influenza. However, the immunogenicity of influenza vaccine is known to be attenuated in these patients. In this study, the immunogenicity of MF59-adjuvanted and non-adjuvanted trivalent influenza vaccines was compared in CKD patients undergoing hemodialysis (HD). Methods: During 2013–2014, 179 CKD patients undergoing HD participated in the study. The patients were randomized into either MF59-adjuvanted vaccine group or non-adjuvanted vaccine group and were immunized with the respective vaccine. Sera were collected prior to vaccination and at 1 month (88 patients in MF59-adjuvanted vaccine group and 86 patients in non-adjuvanted vaccine group) and 6 months post vaccination. Levels of hemagglutination inhibition antibodies were measured. Results: The seroconversion rate of all 3 vaccine strains at 1 month post-vaccination was significantly higher in the MF59-adjuvanted group than in the non-adjuvanted group (47.7% vs. 17.4%, A/H1N1; 42.0% vs. 16.3%, A/H3N2; 31.8% vs. 7.0%, B, P < 0.01). One month post-vaccination, the fold increase in geometric mean titer from pre-vaccination for A/H1N1, A/H3N2 and B viruses was significantly greater in the MF59-adjuvanted group than in the non-adjuvanted group. In elderly patients (≥65 years), the seroconversion rate at 1 month post-vaccination against influenza B strain was higher in the MF59-adjuvanted group than in the non-adjuvanted group (33.3% vs. 7.1%, P = 0.03). Conclusion: The MF59-adjuvanted influenza vaccine showed better immunogenicity than the non-adjuvanted influenza vaccine in CKD patients undergoing HD.

KW - influenza vaccines

KW - MF59 oil emulsion

KW - renal dialysis

UR - http://www.scopus.com/inward/record.url?scp=84997712965&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84997712965&partnerID=8YFLogxK

U2 - 10.1080/21645515.2016.1191717

DO - 10.1080/21645515.2016.1191717

M3 - Article

C2 - 27802078

AN - SCOPUS:84997712965

VL - 12

SP - 2902

EP - 2908

JO - Human Vaccines and Immunotherapeutics

JF - Human Vaccines and Immunotherapeutics

SN - 2164-5515

IS - 11

ER -